Atralin is a drug owned by Dow Pharmaceutical Sciences. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Sep 23, 2014. Details of Atralin's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US5670547 | Moisturizing vehicle for topical application of vitamin A acid |
Sep, 2014
(10 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Atralin is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Atralin's family patents as well as insights into ongoing legal events on those patents.
Atralin's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Atralin's generic launch date based on the expiry of its last outstanding patent is estimated to be Sep 23, 2014 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Atralin Generic API suppliers:
Tretinoin is the generic name for the brand Atralin. 14 different companies have already filed for the generic of Atralin, with Padagis Us having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Atralin's generic
Alternative Brands for Atralin
There are several other brand drugs using the same active ingredient (Tretinoin) as Atralin. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Almirall |
| |||
| Bausch |
| |||
| Concordia |
| |||
| Dow Pharm |
| |||
| Galderma Labs Lp |
| |||
| Sun Pharm |
| |||
| Sun Pharm Inds Inc |
| |||
| Valeant Pharms North |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Tretinoin, Atralin's active ingredient. Check the complete list of approved generic manufacturers for Atralin
About Atralin
Atralin is a drug owned by Dow Pharmaceutical Sciences. Atralin uses Tretinoin as an active ingredient. Atralin was launched by Dow Pharm in 2007.
Approval Date:
Atralin was approved by FDA for market use on 26 July, 2007.
Active Ingredient:
Atralin uses Tretinoin as the active ingredient. Check out other Drugs and Companies using Tretinoin ingredient
Dosage:
Atralin is available in gel form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.05% | GEL | Prescription | TOPICAL |